Upregulation of PD-L1 by various oncogenic mutations such as EGFR, BRAF, and activation of PI3K and JAK-STAT3 in tumor cells are critical pathways modulating tumor immune responses in the TME. The gene discussed is EGFR; the disease is neoplasm.